Strong T-cell costimulation can reactivate tumor antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: Results from a phase - Clinical study

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 71-77

  Schirrmacher, Volker ^a,b   Schlude, Christoph ^a,b   Weitz, Jürgen ^a,b   Beckhove, Philipp ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bispecific antibodies; Colorectal carcinoma; ELI SPOT response; T cell costimulation

Indexed keywords

ATV-NDV-BSHN-CD28 VACCINE; CANCER VACCINE; CD28 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADULT; AGED; ANIMAL; CANCER STAGING; CHO CELL LINE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CRICETULUS; FEMALE; HAMSTER; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

ADULT; AGED; ANIMALS; ANTIGENS, CD28; ANTIGENS, NEOPLASM; CANCER VACCINES; CHO CELLS; COLORECTAL NEOPLASMS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; VACCINATION;

EID: 84917691443     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2692     Document Type: Article

References (28)

1. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection of metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318, 1999.
2. Galon J, Costes A, Sanchez-C abo F, et al: Type, density, and location of immune cells within colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.
3. Ockert D, Schirrmacher V, Beck N, et al: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2: 21-28, 1996.
4. Schirrmacher V, Fournier P and Schlag P: Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Exp Rev Vaccines 13: 117-130, 2014.
5. Schulze T, Kemmner W, Weitz J, et al: Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 58: 61-69, 2009.
6. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
7. Schwartz RH: T cell anergy. Annu Rev Immunol 21: 305-334, 2003.
8. Greenfield EA, Nguyen KA and Kuchroo VK: CD28/B7 costimulation: a review. Crit Rev Immunol 18: 389-418, 1998.
9. Fournier P and Schirrmacher V: Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 27: 35-53, 2013.
10. Aigner M, Janke M, Lulei M, Beckhove P, Fournier P and Schirrmacher V: An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int J Oncol 32: 777-789, 2008.
11. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23: 2439-2453, 2005.
12. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int J Cancer 118: 658-667, 2006.
13. Koch M, Beckhove P, Op den Winkel J, et al: Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg. 244: 986-992, 2006.
14. Sommerfeldt N, Schütz F, Sohn C, Förster J, Schirrmacher V and Beckhove P: The shaping of a polyvalent and highly individual T- cell repertoire in the bone-marrow of breast cancer patients. Cancer Res 66: 8258-8265, 2006.
15. Termeer CC, Schirrmacher V, Bröcker EB and Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T- cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7: 316-323, 2000.
16. Bai L, Koopmann J, Fiola C, Fournier P and Schirrmacher V: Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 21: 685-694, 2002.
17. Brischwein K, Schlereth B, Guller B, et al: MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43: 1129-1143, 2006.
18. Biburger M, Weth R and Wels WS: A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T- cell activation to tumor cells overexpressing ErbB2/HER2. J Mol Biol 346: 1299-1311, 2005.
19. Müller D, Frey K and Kontermann RE: A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother 31: 714-722, 2008.
20. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999.
21. Fournier P, Wilden H and Schirrmacher V: Importance of retinoic acid-inducible gene - and of receptor for Type - interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol 40: 287-298, 2012.
22. Washburn B and Schirrmacher V: Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 21: 85-93, 2002.
23. Grakoui A, Bromley SK, Sumen C, et al: The immunological synapse: a molecular machine controlling T cell activation. Science 285: 221-227, 1999.
24. Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727, 2006.
25. St Clair EW: The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 118: 1344-1347, 2008.
26. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diehl IJ, Pedain C, Oberniedermayr M, Schirrmacher V and Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458, 2001.
27. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hämmerling GJ, Kyewsky B, Hamann A, Umansly V and Schirrmacher V: Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 9: 1151-1157, 2003.
28. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V and Beckhove P: T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 9: 526-534, 2003.